New Statin Guidelines and Diabetes, Are You Confused?
New cholesterol guidelines can be confusing for those with type 2 diabetes. We have dug a bit deeper to help you understand if you need a statin.
It appears that if some doctors have their way, millions more people will be added to the list of those taking statin drugs. At least that is how it seems when one reviews the new guidelines and risk calculator issued by the American Heart Association (AHA) for how to reduce the risk of heart disease. But if you have diabetes, you may be confused.
What the guidelines say
A team of experts from the AHA and the American College of Cardiology have stated that reducing one’s low-density lipoprotein (LDL) cholesterol levels to certain values is no longer the gold standard for determining a person’s risk of developing heart disease over 10 years. Now they believe each individual’s risk factors should be evaluated. That sounds reasonable.
Some of those risk factors include being obese, already having heart disease, being African-American, having high blood pressure, having an LDL level of 190 mg/dL or greater, having a family history of heart disease, or being middle-aged with type 2 diabetes.
Statins and diabetes
If you fall into the latter group, you may be confused. Haven’t studies shown that statins can raise blood glucose levels and/or hemoglobin A1c and/or the risk of type 2 diabetes?
Yes. For example:
A study published online January 9, 2012 in the Archives of Internal Medicine reviewed data from 153,840 postmenopausal women who participated in the Women’s Health Initiative. They reported a 48 percent increased risk of developing type 2 diabetes among women taking statins, including simvastatin, lovastatin, pravastatin, fluvastatin, and atorvastatin.
A more recent article (2013) appearing in Cardiovascular Diabetology pointed out there is “conflicting data…regarding the diabetogenic effects of some statins.” However, the Food and Drug Administration has mandated the labeling of all statins to indicate “an effect of statins on incident diabetes and increase in hemoglobin A1c and/or FPG [fasting plasma glucose].”
The review goes on to note that “the literature suggests that the beneficial effects of most statins on CV [cardiovascular] risk continue to outweigh their diabetogenic risks.” That may be true for some patients with type 2 diabetes, and indeed some patients are already prescribed these drugs.
But a fear among people with type 2 diabetes who are currently not taking statins is that the scene is about to change.